Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma
BACKGROUND Of the 20 known cytokeratins, CK‐19 is expressed in normal urothelium, whereas the recently identified CK‐20 is expressed in urothelial carcinoma cells but not in normal urothelial cells. The aim of this study was to examine whether CK‐20 expression could serve as a noninvasive test in wh...
Gespeichert in:
Veröffentlicht in: | Cancer 1998-01, Vol.82 (2), p.349-354 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 354 |
---|---|
container_issue | 2 |
container_start_page | 349 |
container_title | Cancer |
container_volume | 82 |
creator | Klein, Ami Zemer, Ruth Buchumensky, Victor Klaper, Ronen Nissenkorn, Israel |
description | BACKGROUND
Of the 20 known cytokeratins, CK‐19 is expressed in normal urothelium, whereas the recently identified CK‐20 is expressed in urothelial carcinoma cells but not in normal urothelial cells. The aim of this study was to examine whether CK‐20 expression could serve as a noninvasive test in which malignant urothelial cells in urine are detected and monitored.
METHODS
In the current study, the authors used reverse transcriptase‐polymerase chain reaction (RT‐PCR) methods to determine the expression of CK‐20 in cells separated from the urine of patients with bladder carcinoma. Cells were obtained from the urine of 87 patients divided into the following 2 groups: 1) 14 healthy volunteers without any known history of transitional cell carcinoma (TCC), and 2) 73 patients with hematuria suspected for TCC of the bladder. For control purposes, CK‐20 expression was examined in cells of 1) bladder carcinoma tumors of 5 patients, 2) blood of either patients with bladder carcinoma (n = 5) or healthy controls (n = 5), and 3) three different cell lines. RNA of the various cell pellets was extracted and RT‐PCR was performed with CK‐20 and CK‐19 primers (CK‐19 was used as a marker for normal epithelial cells).
RESULTS
CK‐20 amplification band (370 bp) was obtained with mRNA extracted from TCC cells of either bladder tumor or HT‐29 line (a CK‐20 colon carcinoma line). Sensitivity of the method was found to be 91%, whereas specificity was 67%. Among the 7 false‐positive cases, 3 showed atypia, 3 hyperplasia, and 1 metaplasia, and 2 underwent previously successful TCC tumor removals, suggesting that the CK‐20 test also responded to premalignant lesions. No false‐positive cases were found in the healthy control group. No other preparation, including blood of the patients of with TCC, showed the CK‐20 amplification band.
CONCLUSIONS
These results indicate that CK‐20 is a potential biomarker for noninvasive detection of bladder carcinoma by assaying uroepithelial cells from the voided urine specimen with RT‐PCR. Cancer 1998;82:320‐330. © 1998 American Cancer Society.
Detection of CK‐20 gene expression by reverse transcriptase‐polymerase chain reaction in urinary cytology can serve as a noninvasive method for detecting bladder carcinoma. |
doi_str_mv | 10.1002/(SICI)1097-0142(19980115)82:2<355::AID-CNCR16>3.0.CO;2-Y |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79663100</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79663100</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4796-35472a69d8b28ebca293ee19da757aa923d53fb57c75982bbe8f0b7e53cb8bc83</originalsourceid><addsrcrecordid>eNqFkF1v0zAYhS0EGt3gJyDlAqHtIsUfcW0XhDaFbVSaVomBtHHzynYcMKRJsVON_nscGnoD0m5s2ef4vMcPQqcETwnG9PXxzaJcnBCsRI5JQY-JUhITwk8kndO3jPP5_GzxPi-vy49k9o5N8bRcvqH53SM02T96jCYYY5nzgt0-RYcxfk9HQTk7QAeqKDhRbIJuzn-tg4vRd23W1Znd9t0PF3Tv24ziLK2b4Fsdtn-Upvu6HVzrpLu2j9m9779lptFV5UJmdbC-7Vb6GXpS6ya65-N-hD5fnH8qP-RXy8tFeXaV20KoWc54IaieqUoaKp2xmirmHFGVFlxorSirOKsNF1ZwJakxTtbYCMeZNdJYyY7Qq13uOnQ_Ny72sPLRuqbRres2EdKQGUs4k_F2Z7ShizG4GtbBr9KvgGAYeAMMvGFABwM6-MsbJAUKiTdA4g073sAAQ7lMwl2KfjF22JiVq_bBI-Ckvxx1Ha1u6qBb6-PeRglRlNNk-7Kz3fvGbf-p92C7_5Ybb9hv6z-pyQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79663100</pqid></control><display><type>article</type><title>Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Access via Wiley Online Library</source><source>Wiley Online Library (Open Access Collection)</source><source>Alma/SFX Local Collection</source><creator>Klein, Ami ; Zemer, Ruth ; Buchumensky, Victor ; Klaper, Ronen ; Nissenkorn, Israel</creator><creatorcontrib>Klein, Ami ; Zemer, Ruth ; Buchumensky, Victor ; Klaper, Ronen ; Nissenkorn, Israel</creatorcontrib><description>BACKGROUND
Of the 20 known cytokeratins, CK‐19 is expressed in normal urothelium, whereas the recently identified CK‐20 is expressed in urothelial carcinoma cells but not in normal urothelial cells. The aim of this study was to examine whether CK‐20 expression could serve as a noninvasive test in which malignant urothelial cells in urine are detected and monitored.
METHODS
In the current study, the authors used reverse transcriptase‐polymerase chain reaction (RT‐PCR) methods to determine the expression of CK‐20 in cells separated from the urine of patients with bladder carcinoma. Cells were obtained from the urine of 87 patients divided into the following 2 groups: 1) 14 healthy volunteers without any known history of transitional cell carcinoma (TCC), and 2) 73 patients with hematuria suspected for TCC of the bladder. For control purposes, CK‐20 expression was examined in cells of 1) bladder carcinoma tumors of 5 patients, 2) blood of either patients with bladder carcinoma (n = 5) or healthy controls (n = 5), and 3) three different cell lines. RNA of the various cell pellets was extracted and RT‐PCR was performed with CK‐20 and CK‐19 primers (CK‐19 was used as a marker for normal epithelial cells).
RESULTS
CK‐20 amplification band (370 bp) was obtained with mRNA extracted from TCC cells of either bladder tumor or HT‐29 line (a CK‐20 colon carcinoma line). Sensitivity of the method was found to be 91%, whereas specificity was 67%. Among the 7 false‐positive cases, 3 showed atypia, 3 hyperplasia, and 1 metaplasia, and 2 underwent previously successful TCC tumor removals, suggesting that the CK‐20 test also responded to premalignant lesions. No false‐positive cases were found in the healthy control group. No other preparation, including blood of the patients of with TCC, showed the CK‐20 amplification band.
CONCLUSIONS
These results indicate that CK‐20 is a potential biomarker for noninvasive detection of bladder carcinoma by assaying uroepithelial cells from the voided urine specimen with RT‐PCR. Cancer 1998;82:320‐330. © 1998 American Cancer Society.
Detection of CK‐20 gene expression by reverse transcriptase‐polymerase chain reaction in urinary cytology can serve as a noninvasive method for detecting bladder carcinoma.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/(SICI)1097-0142(19980115)82:2<355::AID-CNCR16>3.0.CO;2-Y</identifier><identifier>PMID: 9445193</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - urine ; Carcinoma, Transitional Cell - blood ; Carcinoma, Transitional Cell - pathology ; Carcinoma, Transitional Cell - urine ; False Positive Reactions ; Female ; Gene Expression Regulation, Neoplastic ; Hematuria - pathology ; Hematuria - urine ; HT29 Cells - pathology ; Humans ; Hyperplasia ; Investigative techniques, diagnostic techniques (general aspects) ; Keratins - analysis ; Keratins - blood ; Keratins - genetics ; Keratins - urine ; Male ; Medical sciences ; Metaplasia ; Middle Aged ; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques ; Polymerase Chain Reaction ; Precancerous Conditions - blood ; Precancerous Conditions - pathology ; Precancerous Conditions - urine ; RNA, Messenger - analysis ; RNA, Messenger - genetics ; Sensitivity and Specificity ; Transcription, Genetic ; Tumor Cells, Cultured ; Urinary Bladder ; Urinary Bladder - pathology ; Urinary Bladder Neoplasms - blood ; Urinary Bladder Neoplasms - pathology ; Urinary Bladder Neoplasms - urine ; Urinary system ; Urothelium - pathology</subject><ispartof>Cancer, 1998-01, Vol.82 (2), p.349-354</ispartof><rights>Copyright © 1998 American Cancer Society</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4796-35472a69d8b28ebca293ee19da757aa923d53fb57c75982bbe8f0b7e53cb8bc83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2F%28SICI%291097-0142%2819980115%2982%3A2%3C355%3A%3AAID-CNCR16%3E3.0.CO%3B2-Y$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2F%28SICI%291097-0142%2819980115%2982%3A2%3C355%3A%3AAID-CNCR16%3E3.0.CO%3B2-Y$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,1434,27929,27930,45579,45580,46414,46838</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2119252$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9445193$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Klein, Ami</creatorcontrib><creatorcontrib>Zemer, Ruth</creatorcontrib><creatorcontrib>Buchumensky, Victor</creatorcontrib><creatorcontrib>Klaper, Ronen</creatorcontrib><creatorcontrib>Nissenkorn, Israel</creatorcontrib><title>Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND
Of the 20 known cytokeratins, CK‐19 is expressed in normal urothelium, whereas the recently identified CK‐20 is expressed in urothelial carcinoma cells but not in normal urothelial cells. The aim of this study was to examine whether CK‐20 expression could serve as a noninvasive test in which malignant urothelial cells in urine are detected and monitored.
METHODS
In the current study, the authors used reverse transcriptase‐polymerase chain reaction (RT‐PCR) methods to determine the expression of CK‐20 in cells separated from the urine of patients with bladder carcinoma. Cells were obtained from the urine of 87 patients divided into the following 2 groups: 1) 14 healthy volunteers without any known history of transitional cell carcinoma (TCC), and 2) 73 patients with hematuria suspected for TCC of the bladder. For control purposes, CK‐20 expression was examined in cells of 1) bladder carcinoma tumors of 5 patients, 2) blood of either patients with bladder carcinoma (n = 5) or healthy controls (n = 5), and 3) three different cell lines. RNA of the various cell pellets was extracted and RT‐PCR was performed with CK‐20 and CK‐19 primers (CK‐19 was used as a marker for normal epithelial cells).
RESULTS
CK‐20 amplification band (370 bp) was obtained with mRNA extracted from TCC cells of either bladder tumor or HT‐29 line (a CK‐20 colon carcinoma line). Sensitivity of the method was found to be 91%, whereas specificity was 67%. Among the 7 false‐positive cases, 3 showed atypia, 3 hyperplasia, and 1 metaplasia, and 2 underwent previously successful TCC tumor removals, suggesting that the CK‐20 test also responded to premalignant lesions. No false‐positive cases were found in the healthy control group. No other preparation, including blood of the patients of with TCC, showed the CK‐20 amplification band.
CONCLUSIONS
These results indicate that CK‐20 is a potential biomarker for noninvasive detection of bladder carcinoma by assaying uroepithelial cells from the voided urine specimen with RT‐PCR. Cancer 1998;82:320‐330. © 1998 American Cancer Society.
Detection of CK‐20 gene expression by reverse transcriptase‐polymerase chain reaction in urinary cytology can serve as a noninvasive method for detecting bladder carcinoma.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - urine</subject><subject>Carcinoma, Transitional Cell - blood</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Carcinoma, Transitional Cell - urine</subject><subject>False Positive Reactions</subject><subject>Female</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>Hematuria - pathology</subject><subject>Hematuria - urine</subject><subject>HT29 Cells - pathology</subject><subject>Humans</subject><subject>Hyperplasia</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Keratins - analysis</subject><subject>Keratins - blood</subject><subject>Keratins - genetics</subject><subject>Keratins - urine</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metaplasia</subject><subject>Middle Aged</subject><subject>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</subject><subject>Polymerase Chain Reaction</subject><subject>Precancerous Conditions - blood</subject><subject>Precancerous Conditions - pathology</subject><subject>Precancerous Conditions - urine</subject><subject>RNA, Messenger - analysis</subject><subject>RNA, Messenger - genetics</subject><subject>Sensitivity and Specificity</subject><subject>Transcription, Genetic</subject><subject>Tumor Cells, Cultured</subject><subject>Urinary Bladder</subject><subject>Urinary Bladder - pathology</subject><subject>Urinary Bladder Neoplasms - blood</subject><subject>Urinary Bladder Neoplasms - pathology</subject><subject>Urinary Bladder Neoplasms - urine</subject><subject>Urinary system</subject><subject>Urothelium - pathology</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkF1v0zAYhS0EGt3gJyDlAqHtIsUfcW0XhDaFbVSaVomBtHHzynYcMKRJsVON_nscGnoD0m5s2ef4vMcPQqcETwnG9PXxzaJcnBCsRI5JQY-JUhITwk8kndO3jPP5_GzxPi-vy49k9o5N8bRcvqH53SM02T96jCYYY5nzgt0-RYcxfk9HQTk7QAeqKDhRbIJuzn-tg4vRd23W1Znd9t0PF3Tv24ziLK2b4Fsdtn-Upvu6HVzrpLu2j9m9779lptFV5UJmdbC-7Vb6GXpS6ya65-N-hD5fnH8qP-RXy8tFeXaV20KoWc54IaieqUoaKp2xmirmHFGVFlxorSirOKsNF1ZwJakxTtbYCMeZNdJYyY7Qq13uOnQ_Ny72sPLRuqbRres2EdKQGUs4k_F2Z7ShizG4GtbBr9KvgGAYeAMMvGFABwM6-MsbJAUKiTdA4g073sAAQ7lMwl2KfjF22JiVq_bBI-Ckvxx1Ha1u6qBb6-PeRglRlNNk-7Kz3fvGbf-p92C7_5Ybb9hv6z-pyQ</recordid><startdate>19980115</startdate><enddate>19980115</enddate><creator>Klein, Ami</creator><creator>Zemer, Ruth</creator><creator>Buchumensky, Victor</creator><creator>Klaper, Ronen</creator><creator>Nissenkorn, Israel</creator><general>John Wiley & Sons, Inc</general><general>Wiley-Liss</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19980115</creationdate><title>Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma</title><author>Klein, Ami ; Zemer, Ruth ; Buchumensky, Victor ; Klaper, Ronen ; Nissenkorn, Israel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4796-35472a69d8b28ebca293ee19da757aa923d53fb57c75982bbe8f0b7e53cb8bc83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - urine</topic><topic>Carcinoma, Transitional Cell - blood</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Carcinoma, Transitional Cell - urine</topic><topic>False Positive Reactions</topic><topic>Female</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>Hematuria - pathology</topic><topic>Hematuria - urine</topic><topic>HT29 Cells - pathology</topic><topic>Humans</topic><topic>Hyperplasia</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Keratins - analysis</topic><topic>Keratins - blood</topic><topic>Keratins - genetics</topic><topic>Keratins - urine</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metaplasia</topic><topic>Middle Aged</topic><topic>Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques</topic><topic>Polymerase Chain Reaction</topic><topic>Precancerous Conditions - blood</topic><topic>Precancerous Conditions - pathology</topic><topic>Precancerous Conditions - urine</topic><topic>RNA, Messenger - analysis</topic><topic>RNA, Messenger - genetics</topic><topic>Sensitivity and Specificity</topic><topic>Transcription, Genetic</topic><topic>Tumor Cells, Cultured</topic><topic>Urinary Bladder</topic><topic>Urinary Bladder - pathology</topic><topic>Urinary Bladder Neoplasms - blood</topic><topic>Urinary Bladder Neoplasms - pathology</topic><topic>Urinary Bladder Neoplasms - urine</topic><topic>Urinary system</topic><topic>Urothelium - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Klein, Ami</creatorcontrib><creatorcontrib>Zemer, Ruth</creatorcontrib><creatorcontrib>Buchumensky, Victor</creatorcontrib><creatorcontrib>Klaper, Ronen</creatorcontrib><creatorcontrib>Nissenkorn, Israel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Klein, Ami</au><au>Zemer, Ruth</au><au>Buchumensky, Victor</au><au>Klaper, Ronen</au><au>Nissenkorn, Israel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>1998-01-15</date><risdate>1998</risdate><volume>82</volume><issue>2</issue><spage>349</spage><epage>354</epage><pages>349-354</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND
Of the 20 known cytokeratins, CK‐19 is expressed in normal urothelium, whereas the recently identified CK‐20 is expressed in urothelial carcinoma cells but not in normal urothelial cells. The aim of this study was to examine whether CK‐20 expression could serve as a noninvasive test in which malignant urothelial cells in urine are detected and monitored.
METHODS
In the current study, the authors used reverse transcriptase‐polymerase chain reaction (RT‐PCR) methods to determine the expression of CK‐20 in cells separated from the urine of patients with bladder carcinoma. Cells were obtained from the urine of 87 patients divided into the following 2 groups: 1) 14 healthy volunteers without any known history of transitional cell carcinoma (TCC), and 2) 73 patients with hematuria suspected for TCC of the bladder. For control purposes, CK‐20 expression was examined in cells of 1) bladder carcinoma tumors of 5 patients, 2) blood of either patients with bladder carcinoma (n = 5) or healthy controls (n = 5), and 3) three different cell lines. RNA of the various cell pellets was extracted and RT‐PCR was performed with CK‐20 and CK‐19 primers (CK‐19 was used as a marker for normal epithelial cells).
RESULTS
CK‐20 amplification band (370 bp) was obtained with mRNA extracted from TCC cells of either bladder tumor or HT‐29 line (a CK‐20 colon carcinoma line). Sensitivity of the method was found to be 91%, whereas specificity was 67%. Among the 7 false‐positive cases, 3 showed atypia, 3 hyperplasia, and 1 metaplasia, and 2 underwent previously successful TCC tumor removals, suggesting that the CK‐20 test also responded to premalignant lesions. No false‐positive cases were found in the healthy control group. No other preparation, including blood of the patients of with TCC, showed the CK‐20 amplification band.
CONCLUSIONS
These results indicate that CK‐20 is a potential biomarker for noninvasive detection of bladder carcinoma by assaying uroepithelial cells from the voided urine specimen with RT‐PCR. Cancer 1998;82:320‐330. © 1998 American Cancer Society.
Detection of CK‐20 gene expression by reverse transcriptase‐polymerase chain reaction in urinary cytology can serve as a noninvasive method for detecting bladder carcinoma.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>9445193</pmid><doi>10.1002/(SICI)1097-0142(19980115)82:2<355::AID-CNCR16>3.0.CO;2-Y</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-543X |
ispartof | Cancer, 1998-01, Vol.82 (2), p.349-354 |
issn | 0008-543X 1097-0142 |
language | eng |
recordid | cdi_proquest_miscellaneous_79663100 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Access via Wiley Online Library; Wiley Online Library (Open Access Collection); Alma/SFX Local Collection |
subjects | Adult Aged Aged, 80 and over Biological and medical sciences Biomarkers, Tumor - analysis Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Biomarkers, Tumor - urine Carcinoma, Transitional Cell - blood Carcinoma, Transitional Cell - pathology Carcinoma, Transitional Cell - urine False Positive Reactions Female Gene Expression Regulation, Neoplastic Hematuria - pathology Hematuria - urine HT29 Cells - pathology Humans Hyperplasia Investigative techniques, diagnostic techniques (general aspects) Keratins - analysis Keratins - blood Keratins - genetics Keratins - urine Male Medical sciences Metaplasia Middle Aged Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Polymerase Chain Reaction Precancerous Conditions - blood Precancerous Conditions - pathology Precancerous Conditions - urine RNA, Messenger - analysis RNA, Messenger - genetics Sensitivity and Specificity Transcription, Genetic Tumor Cells, Cultured Urinary Bladder Urinary Bladder - pathology Urinary Bladder Neoplasms - blood Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - urine Urinary system Urothelium - pathology |
title | Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T20%3A57%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Expression%20of%20cytokeratin%2020%20in%20urinary%20cytology%20of%20patients%20with%20bladder%20carcinoma&rft.jtitle=Cancer&rft.au=Klein,%20Ami&rft.date=1998-01-15&rft.volume=82&rft.issue=2&rft.spage=349&rft.epage=354&rft.pages=349-354&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/(SICI)1097-0142(19980115)82:2%3C355::AID-CNCR16%3E3.0.CO;2-Y&rft_dat=%3Cproquest_cross%3E79663100%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79663100&rft_id=info:pmid/9445193&rfr_iscdi=true |